Acrannolife, a cutting-edge healthcare startup, is making waves in the world of diagnostics with its innovative approach to detecting and monitoring chronic and infectious diseases.
Founded in 2018 by Avinash Ramani and Agragesh Ramani, Acrannolife has developed a revolutionary non-invasive diagnostic technology, which is transforming chronic disease care and offering groundbreaking solutions for post-transplant patients.
With its flagship platform, Trunome, the company is leading the way in early disease detection, promising to improve clinical outcomes and positively impact over a billion lives globally.
Addressing the Gaps in Chronic Disease Diagnosis
Chronic diseases like kidney failure, heart disease, and organ transplant rejection are among the leading causes of morbidity and mortality worldwide.
The current methods of monitoring these conditions are often invasive, costly, and sometimes unreliable.
For transplant patients, especially, ongoing organ health monitoring is critical to avoid rejection, yet traditional methods are cumbersome and can lead to complications.
Acrannolife saw an opportunity to disrupt this space and transform how healthcare professionals detect and manage these conditions.
Trunome and Liquid Biopsy Technology
Acrannolife’s flagship technology, Trunome, is a non-invasive blood test that allows for early detection and continuous monitoring of chronic diseases, including organ health in post-transplant patients.
What sets Trunome apart is its proprietary diagnostic platform, which leverages the power of liquid biopsy, a groundbreaking method of using blood and urine to detect biomarkers of disease without needing invasive tissue samples.
The liquid biopsy technology enables doctors to detect early signs of organ rejection or disease progression, making treatment plans more effective and tailored to individual patients.
Unlike traditional biopsies, which require invasive surgery, Trunome’s method is quick, safe, and far less painful, providing timely results that improve clinical decision-making and patient outcomes.
Monitoring Organ Health Across Multiple Systems
Acrannolife’s expertise is not limited to a single organ system. Trunome specializes in kidney, liver, heart, lungs, and pancreas care.
With post-transplant care being a crucial area of focus, the company is ensuring that patients can regularly monitor the health of their transplanted organs and avoid potential complications through its non-invasive test.
The diagnostic test is designed to help doctors detect early signs of rejection, helping improve long-term transplant success rates.
Revolutionizing COVID-19 Testing
Beyond chronic disease monitoring, Acrannolife is also making strides in infectious disease detection.
In collaboration with the Indian Council of Medical Research (ICMR), the company has developed COVIQWIK, a COVID-19 testing kit based on the advanced RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification) technology.
This rapid diagnostic test provides results in under an hour, offering a scalable solution for mass testing and making public spaces safer.
The RT-LAMP method is not only more time-efficient than traditional PCR tests but is also highly sensitive and accurate, ensuring quick results even in remote or under-resourced areas.
A Mission to Impact Over a Billion Lives
Acrannolife is on a mission to positively impact over a billion lives by democratizing access to early disease detection.
With their innovative technologies, they aim to address some of the most pressing healthcare challenges, from chronic disease management to infectious disease control.
Their goal is to make diagnostics more accessible, faster, and affordable for people around the world.
Recognition and Awards
Acrannolife’s innovative work has not gone unnoticed. The company has been recognized with several prestigious awards, including a felicitation by the Honourable President of India for its contribution to healthcare innovation.
Additionally, it has been named one of India’s top innovative startups by the India Innovation Growth Program (IIGP), a collaboration with Stanford University, the University of Texas, and the Government of India.
Acrannolife’s groundbreaking work has also earned them top honors at India’s biggest innovation competition, the ET-POI, organized by the Department of Science & Technology (DST) and the Center for Innovation Incubation and Entrepreneurship at IIM Ahmedabad.
The Future of Diagnostics
As Acrannolife continues to grow, its commitment to advancing healthcare through innovation and technology remains steadfast.
The company is currently applying its proprietary molecular counting platform to revolutionize early disease detection, including in the area of cancer, where liquid biopsy can potentially identify tumors earlier and more accurately than traditional methods.
With an unwavering focus on patient-centric care and continuous innovation, Acrannolife is poised to become a global leader in precision diagnostics, driving change in how chronic and infectious diseases are detected, monitored, and treated.
